APLM logo

APOLLOMICS INC

APLMNASDAQ
πŸ† #4226 by market capUS Equity
$19.65β–Ό $1.30 (βˆ’6.21%)
Market closed Β· at close
πŸ””
Track APLM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.2%
7dβ–² 0.0%
14dβ–² 0.0%
30dβ–Ό 10.7%
ytdβ–² 5.1%
1yβ–² 23.4%
🏦Market Cap
$57M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$19.65 – $19.65
52-Week Range
$12.58 – $28.29
Volume (shares)
219
Avg Volume (shares)
β€”
Shares Outstanding
2.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-18.93
Dividend Yield
β€”
Dilution (1yr)
βˆ’61.8%
APLM logo

APOLLOMICS INC

APLM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9Mβ–² +4192.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.0%β–Ό βˆ’3.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$9Mβ–Ό βˆ’77.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$10Mβ–Ό βˆ’64.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
421Kβ–Ό βˆ’61.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3Mβ–Ό βˆ’$6M YoY
StockOtter Β· stockotter.space

About APOLLOMICS INC

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.